Nanobiotix (NBTX) Provides Business Update, Reports FY22 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Wall St falls as bond yields test multi-decade highs
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
April 24, 2023 7:33 PM EDTPivotal Phase 3 trial NANORAY-312 ongoing globally with 104 sites activated in 25 countries to date; interim efficacy analysis after 67% of planned progression free survival (PFS) events expected in H2 2024, as plannedFinal data from Study 102 in head and neck cancer expected in H2 2023First pancreatic cancer data expected from MD Anderson trial in H2 2023Chief Medical Officer with strategically aligned multidisciplinary experience in oncology expected to... More
